Matrix metalloproteinase-25 has a functional role in mouse secondary palate development and is a downstream target of TGF-β3 by Brown, Graham D & Nazarali, Adil J
RESEARCH ARTICLE Open Access
Matrix metalloproteinase-25 has a functional role
in mouse secondary palate development and is a
downstream target of TGF-b3
Graham D Brown, Adil J Nazarali
*
Abstract
Background: Development of the secondary palate (SP) is a complex event and abnormalities during SP
development can lead to cleft palate, one of the most common birth disorders. Matrix metalloproteinases (MMPs)
are required for proper SP development, although a functional role for any one MMP in SP development remains
unknown. MMP-25 may have a functional role in SP formation as genetic scans of the DNA of human cleft palate
patients indicate a common mutation at a region upstream of the MMP-25 gene. We report on the gene
expression profile of MMP-25 in the developing mouse SP and identify its functional role in mouse SP
development.
Results: MMP-25 mRNA and protein are found at all SP developmental stages in mice, with the highest expression
at embryonic day (E) 13.5. Immunohistochemistry and in situ hybridization localize MMP-25 protein and mRNA,
respectively, to the apical palate shelf epithelial cells and apical mesenchyme. MMP-25 knockdown with siRNA in
palatal cultures results in a significant decrease in palate shelf fusion and persistence of the medial edge
epithelium. MMP-25 mRNA and protein levels significantly decrease when cultured palate shelves are incubated in
growth medium with 5 μg/mL of a TGF-b3-neutralizing antibody.
Conclusions: Our findings indicate: (i) MMP-25 gene expression is highest at E12.5 and E13.5, which corresponds
with increasing palate shelf growth downward alongside the tongue; (ii) MMP-25 protein and mRNA expression
predominantly localize in the apical epithelium of the palate shelves, but are also found in apical areas of the
mesenchyme; (iii) knockdown of MMP-25 mRNA expression impairs palate shelf fusion and results in significant
medial edge epithelium remaining in contacted areas; and (iv) bio-neutralization of TGF-b3 significantly decreases
MMP-25 gene expression. These data suggest a functional role for MMP-25 in mouse SP development and are the
first to identify a role for a single MMP in mouse SP development.
Background
Orofacial clefts are some of the most common birth dis-
orders today. Typically, they are disfiguring, can affect
respiration, speech, and eating, and require many sur-
geries to repair. The two main types of orofacial clefts
are cleft lip with or without cleft palate (CL/P) and cleft
palate (CP) alone. CL/P occurs in approximately 0.2 to
2.3 births per 1000 and CP in 0.1 to 1.1 per 1000 births
[1]. CL/P can affect the primary palate (PP), in which
the four maxillary incisors are set at the front of the
mouth, or both the PP and secondary palate (SP). The
SP is posterior to the PP and forms the main barrier
between the oral and nasal cavities. Similarly, CP can
affect the SP or both the PP and SP.
Development of the SP begins around embryonic day
(E) 12.0 in mice and in week six during human gesta-
tion. Due to developmental similarities between mice
and humans, the mouse is an ideal model animal in
which to study SP development. Initially, the SP exists
as two shelves that arise from maxillary prominences on
either side of the tongue. These shelves will grow down-
ward alongside the tongue then quickly elevate when
the tongue depresses, ultimately growing together
around E14.0. With their medial edges in contact, the
two shelves fuse together and the epithelial cells at the
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E15.5-E16.0, this MES has degraded and a solid, conflu-
ent SP remains (reviewed in [2,3]). Development of the
SP is a carefully coordinated event and requires the
actions of many proteins, including transcription factors
[4], growth factors and their receptors, and tissue re-
modeling enzymes (reviewed in [5]). Any problem with
shelf growth, elevation, tongue depression, shelf fusion,
or MES degradation can result in a CP.
Among the proteins required for SP development are
the matrix metalloproteinases (MMPs). These are a
group of proteases with extra-cellular matrix substrates
that require coordination of a zinc ion at the centre of
the catalytic domain to be active. The MMPs are
broadly classed into two categories: the secreted and the
membrane-associated. They are synthesized intra-
cellularly as pro-enzymes and activated via cleavage of
their pro-domain in the Golgi network or extra-
cellularly (reviewed in [6]). Treatment of in vitro SP
cultures with a general chemical inhibitor of the MMPs
results in impaired palate shelf fusion and persistence of
t h em e d i a le d g ee p i t h e l i u m( M E E )w h e r et h es h e l v e s
make contact [7]. However, the MMP family contains
25 members and which one of the MMPs is playing a
functional role in SP development is not clear. One can-
didate is MMP-25 (Membrane-type (MT) 6-MMP;
Leukolysin), as a genetic analysis of human CP patients
reveals a potential association between MMP-25 and
CL/P [8].
MMP-25 is a membrane-associated MMP first cloned
from leukocytes but later found in most tissues exam-
ined [9,10]. This protein appears to have roles in both
healthy and diseased systems. In healthy systems,
MMP-25 can act as both an extra-cellular protease and
an activator of some secreted pro-MMPs (reviewed in
[11]); however, MMP-25 is also over-expressed in cer-
tain cancers and appears to play a role in their progres-
sion [12,13].
Despite evidence to support a functional role for
MMPs in SP development, no further investigations of
individual MMPs and their role in SP formation have
been conducted and thus the role of MMP-25 in SP
development is currently unknown. To our knowledge,
this study represents the first work done on MMP-25 in
the mouse SP.
Using quantitative real-time PCR, in situ hybridization
(ISH), western blot analysis, and immunohistochemistry
(IHC), we show MMP-25 mRNA and protein are
expressed at all stages of the developing mouse SP with
a significant down-regulation at approximately E15.5 as
the MES degrades and SP development comes to an
end. Using an in vitro culture method and MMP-
25-specific small, interfering RNA (siRNA), we show
in vitro SP cultures treated with MMP-25 siRNA exhibit
significantly decreased fusion success and increased per-
sistence of the MEE. Lastly, addition of a TGF-b3-neu-
tralizing antibody to in vitro SP cultures results in
significantly decreased MMP-25 mRNA and protein
expression, providing evidence that MMP-25 is a down-
stream target of TGF-b3 signaling.
Results and Discussion
MMP-25 is expressed in the developing SP at all stages
Quantitative real-time PCR and ISH confirm MMP-25
mRNA expression in the embryonic mouse SP at all
developmental stages (Figs. 1A, 2I-P). Expression of
MMP-25 mRNA increases from E12.5 to E13.5, where its
expression is strongest, before decreasing at E14.5 and
even further by E15.5. MMP-25 mRNA levels are signifi-
cantly decreased at E15.5 relative to E12.5 and E13.5 (p <
0.05). The increased expression of MMP-25 at E12.5 and
E13.5 suggests a role for MMP-25 in promoting palate
shelf growth. At this stage in development, the palate
shelves are budding from the maxilla and growing down-
ward alongside the tongue. A decline in MMP-25 expres-
sion occurs as the shelves are fusing (E14.5) and the MES
is degrading (E15.5). Western blot analysis indicates
MMP-25 protein expression levels parallel mRNA levels
in the embryonic mouse SP (Fig. 1B). MMP-25 appears
as a band of approximately 55 kilodaltons (kDa), which
corresponds to previously published reports of a 57 kDa
molecular weight for MMP-25 [13,14].
MMP-25 protein and mRNA levels are highest in the
epithelium of the palate shelves
IHC and ISH indicate MMP-25 protein and mRNA
localize more strongly to the epithelium of the palate
shelves than the underlying mesenchyme (Fig. 2). At
E12.5 and E13.5, the strongest immunofluorescence is
detected in the epithelium of the palate shelves although
staining is also visible in the apical mesenchyme
( F i g .2 A ,E ;2 B ,F ;2 I ,M ;2 J ,N .T h e s et w os t a g e sr e p r e -
sent continued palate shelf growth alongside the tongue
before the shelves elevate and make contact along their
medial edges. At E14.5, the palate shelves are fusing
along their medial edges and immunofluorescence
shows strong MMP-25 expression in the epithelium of
the palate shelves (Fig. 2C, G; 2K, O) with expression
also visible in the underlying mesenchyme. At E15.5, the
MES is degrading and little epithelium is left between
the two palate shelves (Fig. 2D, H; 2L, P). MMP-25
immunofluorescence at this stage is noticeably weaker
than from E12.5 to E14.5, but remains prominently in
the epithelium as indicated by the oral epithelium and a
degrading remnant of the MES (Fig. 2L, P). This decline
in MMP-25 expression at E15.5 coincides with a con-
firmed decline in MMP-25 mRNA and protein levels
(Fig. 1A, B). MMP-25 immunofluorescence in the SP
Brown and Nazarali BMC Developmental Biology 2010, 10:93
http://www.biomedcentral.com/1471-213X/10/93
Page 2 of 9Figure 1 Matrix metalloproteinase-25 (MMP-25) mRNA and protein are expressed in the developing mouse palate at all stages.( A )
Quantitative real-time PCR indicates a significant down-regulation in MMP-25 mRNA levels at E15.5 compared to E12.5 and E13.5 (p < 0.05;
n = 4 for all stages). Error bars indicate standard error of the mean. (B) Western blot analysis displays a reduction in MMP-25 protein levels at
E15.5 relative to E12.5 and E13.5. GAPDH was used as a loading control.
Figure 2 Localization of matrix metalloproteinase-25 (MMP-25) protein and mRNA expression in the developing mouse palate. (A-H)
Immunofluorescent images of MMP-25 protein expression (red) colocalized with Hoechst nuclear staining (blue). (I-P) In situ hybridization of
MMP-25 mRNA expression (green). Expression of MMP-25 appears stronger in the epithelium of the palate shelves than in the underlying
mesenchyme. (E-H) Enhanced views of highlighted areas from A-D. (M,P) Enhanced views of highlighted areas from I-L. For A-D and I-L, scale bar
indicates 50 μm. For E-H and M-P, scale bar indicates 25 μm.
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mesenchymal cells, which is expected as MMP-25 is a
membrane-associated MMP [15]. The data indicating
stronger MMP-25 expression in apical areas of palate
shelf growth from E12.5 and E13.5 suggest MMP-25
may play a role in facilitating this growth, possibly by
removing extra-cellular matrix barriers to increased cell
proliferation and movement and/or by activating pro-
MMPs that could do the same [11,16].
MMP-25 has a functional role during mouse SP formation
To determine if MMP-25 is playing a functional role
during mouse SP formation, MMP-25 expression was
knocked down in vitro using MMP-25 siRNA and whole
SP cultures as previously described [17,18]. Addition of
Stealth™ RNAi MMP-25 siRNA (Invitrogen) to a final
concentration of 500 nM resulted in decreased palate
shelf fusion and persistence of the MEE in vitro as evi-
denced by representative hematoxlyin and eosin-stained
palatal sections (Fig. 3). While the wild-type and nega-
tive control siRNA palatal cultures fused normally, the
palatal cultures treated with MMP-25 siRNA seemed
l a r g e l yu n a b l et op r o g r e s st ot h ef u s i o ns t a g ed e s p i t e
making contact. Interestingly, the phenotype of our
MMP-25 siRNA-treated palatal cultures (Fig. 3C) after
72 h incubation is very similar to the phenotype of
other in vitro palatal cultures treated with a general che-
mical inhibitor of the MMPs [7]. To obtain a more
objective measure of the MMP-25 siRNA effects, serial
sections of preserved and frozen palatal cultures were
generated. Sections examined by light microscopy were
assigned a score between 1 and 5 based upon fusion
success [19] (see Methods). For each palatal culture
examined, the scores were combined and averaged to
obtain a mean fusion score (MFS) and these MFSs
themselves averaged for an entire group (Table 1). The
wild-type control palatal cultures (n = 10) had a cumu-
lative MFS of 4.14 while the scrambled duplex siRNA
negative control group (n = 10) had a MFS of 4.13.
These scores put both groups solidly in the fusion cate-
gory and indicate minimal non-specific siRNA or trans-
fection reagent effects. The MFS of the palatal culture
group treated with 500 nM MMP-25 siRNA (n = 10)
was significantly lower at 2.50 (Kruskal-Wallis test; p <
0.05). To ensure the drop in MFS could be attributed to
MMP-25 mRNA and subsequent protein knockdown,
quantitative real-time PCR and western blot analyses
were carried out on RNA and protein isolated from the
remaining palatal cultures from each group. The
MMP-25 siRNA knocked down both MMP-25 mRNA
and protein levels efficiently (Fig. 4). Quantitative real-
time PCR shows a significant decrease in MMP-25
mRNA levels in the MMP-25 siRNA-treated group rela-
tive to the control groups (Fig. 4A; p < 0.05), and wes-
tern blot analysis displays a sharp reduction in MMP-25
protein levels in the treated group when compared to
the control groups (Fig. 4B). Taken together, these data
s u g g e s taf u n c t i o n a lr o l ef o rM M P - 2 5i nm o u s eS P
development.
MMP-25 is a downstream transcriptional target of TGF-b3
The secreted growth factor TGF-b3 is vital to the suc-
cessful formation of the mouse SP [20,21]. TGF-b3
exerts biological activity through its receptors, which are
tyrosine kinases, and its intra-cellular mediators, the
Smad proteins, which translocate to the nucleus affect-
ing gene transcription following phosphorylation (see
[22] for a review). An examination of the proximal pro-
moter sequence of MMP-25 obtained from the Eukaryo-
tic Promoter Database http://www.epd.isb-sib.ch/
displayed repeating sequences of 5’-GTCT-3’ and
5’-CAGA-3’ (data not shown), which are sites of prefer-
ential binding by the Smad proteins [23-25]. Due to the
existence of Smad binding sites just upstream of the
MMP-25 transcription start site and given the important
role of TGF-b3 in palate development [20,21], we
hypothesized MMP-25 could be a target of TGF-b3.
MMP-25 mRNA and protein levels significantly
decreased (p < 0.05) following 24 h incubation with
5 μg/mL of a TGF-b3-neutralizing antibody (Figs. 5, 6).
This decreased expression of MMP-25 is not due to
apoptotic cell death as activated caspase3 was not
detected in palatal cultures treated with TGF-b3-
Figure 3 Representative hematoxylin and eosin staining of
embryonic day (E) 13.0 in vitro cultured palates after 72 h. (A)
Palate shelves incubated for 72 h with growth medium fused
normally. (B) Palate shelves grown with 500 nM scrambled control
siRNA fused normally. (C) Palate shelves grown with 500 nM matrix
metalloproteinease-25-specific siRNA did not fuse normally and
contained considerable medial edge epithelium compared to the
control groups.
Table 1 Mean fusion scores for palatal cultures
Culture
a Number MFS
b
Wild-type 10 4.14
Scrambled Control siRNA 10 4.13
MMP-25 siRNA 10 2.50
aPalate shelves were removed at E13.0 and cultured for 72 h prior to
sectioning and assessment of shelf fusion.
bMean of scores based on the success of fusion as per [19].
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Page 4 of 9neutralizing antibody (Fig. 7). MMP-25 mRNA and pro-
tein levels between the groups treated with different
concentrations of the TGF-b3-neutralizing antibody
were not significantly different. To confirm the decrease
in MMP-25 mRNA and protein could be attributed to a
loss of TGF-b3 activity in the cultures, western blot ana-
lysis was carried out on protein isolated from the four
groups with a phospho-Smad1 antibody. Levels of
phospho-Smad1 were inversely correlated with the con-
centration of the TGF-b3-neutralizing antibody; as the
bio-neutralizing antibody concentration went up, phos-
pho-Smad1 levels went down (Fig. 8).
The strength of the MMP-25 gene expression knock-
down by the TGF-b3-neutralizing antibody is supported
by several lines of evidence. First, expression of MMP-
25 is found in the palate shelf in a manner very similar
to the expression pattern of TGF-b3[ 2 6 ] .S e c o n d ,
TGF-b1i so n l yd e t e c t a b l ea f t e rt h eh o r i z o n t a lp a l a t a l
shelf stage [26], and expression of TGF-b1f r o mt h e
TGF-b3 locus cannot completely rescue TGF-b3-
induced cleft palate [27]. Spatially, TGF-b2 expression is
restricted to the palate mesenchyme and is not apparent
until the palate shelves are fusing [26]. Thus, TGF-b2
expression is temporally and spatially distinct from and
unlikely to contribute to MMP-25 expression. This evi-
dence also suggests TGF-b3-specific activity in the
developing SP that cannot be compensated for by other
TGF-b isoforms [27]. A link between the MMPs and
TGF-b3 is not without precedent; MMP-13 expression
has been demonstrated to be downstream of TGF-b3
[7]. These data suggest MMP-25 is a direct transcrip-
tional target for TGF-b3 in mouse SP development and
could be a target for TGF-b3 elsewhere as well.
Conclusions
MMP-25 mRNA and protein are expressed in the
developing mouse SP from stages E12.5 to E15.5, and
protein expression largely localizes to the epithelium of
the palate shelves. Expression of MMP-25 mRNA and
protein is highest at E13.5 and mRNA levels signifi-
cantly decrease by E15.5. IHC and ISH analysis of
MMP-25 protein and mRNA expression, respectively,
show MMP-25 is most abundant in the epithelium of
the palate shelves although expression is also visible in
the underlying mesenchyme. Expression in the
mesenchyme appears strongest in apical areas
Figure 4 Confirmation of specific matrix metalloproteinase-25 (MMP-25) knockdown for in vitro palatal cultures. (A) Quantitative real-
time PCR shows a significant decrease in MMP-25 mRNA levels from in vitro cultures following treatment with 500 nM MMP-25 siRNA (p < 0.01).
Error bars indicate standard error of the mean. (B) MMP-25 protein expression is reduced in in vitro palatal cultures following treatment with
MMP-25 siRNA. b-Actin was used as a loading control.
Figure 5 Matrix metalloproteinase-25 (MMP-25) mRNA and protein expression is decreased in in vitro palatal cultures following
treatment with a TGF-b3-neutralizing antibody. (A) Quantitative real-time PCR data indicates a significant reduction in MMP-25 mRNA levels
in in vitro palatal cultures after exposure to a TGF-b3-neutralizing antibody. (B) MMP-25 protein is decreased upon bio-neutralization of TGF-b3.
b-Actin was used as a loading control.
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Page 5 of 9immediately adjacent to the overlying epithelium at
E12.5 and E13.5 where it may play a role in facilitating
g r o w t h .A tE 1 4 . 5 ,M M P - 2 5p r o t e i na n dm R N Ae x p r e s -
sion appear highest in medial epithelia (Fig. 2C,G; 2K,
O) as palatal shelves come together to fuse. At E15.5, a
down-regulation of expression is evident when fusion
is nearing completion.
Through the use of palatal cultures, we demonstrate
treatment with an MMP-25-specific siRNA decreases
palate shelf fusion and results in significant persistence of
MEE in vitro.T h i si st h ef i r s tr e p o r ts u p p o r t i n gaf u n c -
tional role for a single MMP in mouse SP development.
Our in vitro palatal culture work coupled with the IHC,
ISH, and real-time PCR data suggest MMP-25 plays a
k e yr o l ei np a l a t es h e l fg r o w t ha tE 1 2 . 5a n dE 1 3 . 5b y
removing extra-cellular matrix barriers that would hinder
cell proliferation and movement. The substrates of
MMP-25 include type IV collagen, fibronectin, and fibrin
[28], which are all components of the extra-cellular
matrix and barriers to cell proliferation and movement.
IHC analysis of MMP-25 protein expression in colorectal
tissue sections shows MMP-25 is strongly expressed on
the leading edge of tumours and positively correlates to
an invasive cancer [13]. Our results indicate MMP-25
p r o t e i ne x p r e s s i o ni nt h ed e v e l o p i n gm o u s eS Pi sa l s o
higher on the apical, or leading, edge. Most compellingly,
double knock-out of MMP-14 (MT1-MMP) and
MMP-16 (MT3-MMP) results in a cleft palate in mice
due to impaired growth of the palate shelves [29], which
implies a role for proteolytic enzymes in mouse SP devel-
opment even though no palate defects were reported for
the single gene knock-out of either MMP-16 [29] or
Figure 7 (A,B,E) Immunohistochemical staining for activated caspase3. Little or no activated caspase 3 could be identified in control palatal
cultures (E) or in TGF-b3-neutralizing antibody-treated palatal culture (A). (B) Section of E13.5 digits exhibiting caspase3 activity as positive
control. (C) Immunohistochemistry (IHC) section of adult mouse heart exhibiting MMP-25 expression (red) as positive control colocalized with
Hoechst nuclear staining (blue). (G) IHC section of adult mouse heart with only the secondary antibody as negative control. (D) ISH of E12.5
palatal section with scrambled Dig-labeled oligo probe as negative control. (F) IHC of E13.5 palate showing Hoxa2 expression as positive control
[4]. (H) IHC of E12.5 palatal culture with only the secondary antibody colocalized with Hoechst nuclear staining (blue) as negative control. Scale
bar indicates 50 μm.
Figure 6 (A, C) Embryonic day (E) 13.0 in vitro cultured control
palate after 72 h, (B,D) E13 in vitro cultured palate (treated
with TGF-b3-neutralizing antibody, 10 μg/mL) after 72 h. (A,B)
Hematoxylin and eosin (H&E) stained sections. (C,D)
Immunohistochemistry of MMP-25 (red) colocalized with Hoechst
nuclear staining (blue). TGF-b3-neutralizing antibody-treated culture
inhibited palatal fusion (B) and showed weaker MMP-25 protein
expression (D). Scale bar indicates 50 μm.
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MMP-16 when knocked out on their own may have been
compensated for by MMP-25, which is also a proteolytic
membrane-associated MMP, just as the collagenolytic
activity of MMP-16 was compensated for by MMP-14 in
previous experiments [29]. Our results indicate that
MMP-25 may be the key proteolytic enzyme among the
MMPs during mouse SP formation.
Our treatment of whole palatal cultures with a TGF-
b3-neutralizing antibody in the culture medium resulted
in a significant decrease in MMP-25 mRNA and protein.
Thus, we have established a link between MMP-25 and
TGF-b3 in the developing mouse SP that warrants
further investigation.
Overall, what is known about MMP-25 in embryonic
development remains limited.T h i si st h ef i r s tr e p o r tt o
identify a role for a single MMP in mouse SP development
and validates the link between MMP-25 and CL/P identi-
fied from human genetic analysis scans of CP patients [8].
Methods
Quantitative real-time PCR
All animal procedures were approved by the Animal
Research Ethics Board and the Institutional Animal Care
and Use Committee of the University of Saskatchewan.
Whole palate shelves were dissected from CD1 mouse
embryos at the time periods indicated (E12.5-E15.5).
Total RNA was isolated using an RNeasy® Mini Kit
(Qiagen; Mississauga, ON, Canada) and reverse-
transcribed to cDNA using SuperScript™ RNase
H-Reverse Transcriptase according to the manufacturer’s
protocol (Invitrogen; Carlsbad, CA). Gene expression was
quantified using the Taqman® primers and labeled probe
system (Applied Biosystems; Foster City, CA) and a real-
time PCR machine (ABI 7300) from Applied Biosystems.
All reactions were performed using the Taqman Univer-
sal Master Mix (2X), FAM-labeled Taqman Gene Expres-
sion assays for the MMP-25 gene, VIC-labeled Taqman
Endogenous Control b-Actin, and 10 ng of cDNA. Ther-
mocycling parameters were as follows: 2 min at 50°C,
10 min at 95°C, 40 cycles of 15 s at 95°C plus 70 s at
60°C. Taqman gene expression assays have all been tested
to have efficiencies not significantly different from
1 (Applied Biosystems). However, to ensure that the pri-
mer sets were working properly and that multiplexing
t h eg e n es p e c i f i ca n db-Actin primers did not result in
altered amplification efficiencies, the primer sets were
examined individually and in complex with b-Actin.
Standard curve reactions were run using 1, 10, and
100 ng of palate cDNA and amplification efficiency was
calculated using the equation E = 10
(-1/slope standard curve)
-1 × 100%. In all cases, the efficiency was required to be
between 90-110% for both the gene specific and b-Actin
primers sets before analysis continued. In most cases, the
a p p r o p r i a t ee f f i c i e n c i e sw e r ep o s s i b l eu s i n g1μLo ft h e
gene specific primer and probe solution and 0.25 μLo f
the b-Actin primer and probe set per reaction. All com-
parisons were performed using the relative quantification
(RQ) software (Applied Biosystems). For all quantitative
real-time PCR, n = 4 with four replicates and error bars
indicating the standard error of the mean. Real-time data
were normalized to E15.5 (Fig. 1A) or wild-type expres-
sion (Figs. 4A, 5A) and expressed as relative quantifica-
tion values compared to either E15.5 (Fig. 1A) or wild-
type/untreated expression (Figs. 4A, 5A).
Western blot analysis
Total protein was isolated using a modified radioimmuno-
precipitation assay (RIPA) buffer protocol. Briefly, palatal
tissue was homogenized in RIPA buffer (5 mM ethylene-
diaminetetraacetic acid, 10 mM TRIS pH 8.0, 0.1% sodium
deoxycholate, 0.01% sodium dodecyl sulfate (SDS), 1% Tri-
ton X-100, 150 mM sodium chloride, 1 μg/mL aprotinin,
1 μg/mL pepstatin). Homogenized samples were centri-
fuged at 11,000 rpm at 4°C for 15 min. Supernatant total
protein content was quantified using a DC Protein Assay
Kit (Bio-Rad; Mississauga, ON, Canada) and separated
using SDS poly-acrylamide gel electrophoresis with a
10.0% separating gel. Proteins were transferred to a polyvi-
nylidene fluoride membran ea n dp r o b e df o rp r o t e i n
expression [4]. Primary antibodies employed were MMP-
25 (rabbit polyclonal; Santa-Cruz Biotechnologies, Santa
Figure 8 Western blot analysis against phospho-Smad1 shows a TGF-b3-neutralizing antibody concentration-dependent effect.
Approximately 10 μg of total protein was separated via SDS-PAGE and probed with an anti-phospho-Smad1 antibody (Cell Signaling
Technology; 1:500). An anti-b-actin antibody was used to assess loading equivalence (Santa Cruz; 1:1000).
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Santa Cruz, CA; 1:1000), and GAPDH (rabbit polyclonal;
Sigma-Aldrich, Oakville, ON, Canada; 1:15,000).
Immunohistochemistry
Embryonic mouse heads were preserved in freshly-pre-
pared 4.0% paraformaldehyde (4%PFA) and dehydrated
in 30.0% sucrose at 4°C. Frozen coronal sections (8.0 μm)
were prepared and placed on microscope cover-slips
coated with 0.50% gelatin. IHC with a primary anti-
MMP-25 antibody (1:50; Santa Cruz Biotechnology Inc.)
was carried out as follows: two washes in 1 × PBS for
30 min each followed by a 20 s exposure to pepsin
digest-all solution (Zymed, San Francisco, CA), which
was washed off by immersion in the 1 × PBS for an addi-
tional 3 min; blocking in solution (3% skim milk, 0.1%
Triton X-100 in 1 × PBS) at room temperature for 1.5 h;
incubation with 100 μL of the primary antibody, made up
i n1×P B S ,f o r2ha tr o o mt e m p e r a t u r ef o l l o w e db y
overnight at 4°C; two washes in 1 × PBS for 5 min each;
incubation with 100 μLo fA l e x aF l u o r ® 594 goat anti-
rabbit IgG secondary antibody (1:400; Molecular Probes,
E u g e n e ,O R ) ,m a d eu pi n1 ×P B S ,f o r2ha tr o o mt e m -
perature in the dark; two washes in 1 × PBS for 5 min
each; and mounting onto glass microscope slides using
ProLong® Gold antifade reagent (Invitrogen). IHC was
evaluated by observing sections on an Olympus BX40
fluorescent microscope (Olympus America Inc., Center
Valley, PA) at an emission wavelength of 613 nm. Images
were taken using Image-Pro Plus (v. 6.2; MediaCyber-
netics, Inc., Bethesda, MD). Determination of non-
specific staining was assessed by substituting 100 μLo f
the secondary antibody in lieu of 100 μLo ft h ep r i m a r y
antibody solution (Fig. 7). All preceding and subsequent
steps were carried out as described above [4]. Positive
control IHC (Fig. 7) was obtained using adult mouse
heart sections where MMP-25 expression is high [10].
In situ hybridization
Embryos were fast frozen in isopentane on dry ice and
stored at -80°C before use. Methodology for ISH was
modified from the GeneDetect® protocol. In brief, pala-
tal tissues were sectioned (8 μm) on poly-L-lysine coated
slides and incubated in RNase free 4% PFA (in PBS, pH
7.2) for 10 min followed by rinsing in PBS for 2 × 5
min. This was followed by 10 s treatment with 10 μg/
mL of proteinase K and rinsing in PBS for 2 × 5 min.
Sections were incubated in 100% ethanol for 5 min and
air dried. Sections were prehybridized in hybridization
buffer (GeneDetect®) at 45°C for 3 h in a humidified
chamber. This was followed by incubation in hybridiza-
tion buffer containing the MMP-25 DIG-labeled (Inte-
grated DNA Technologies) probe (4 ng/μL for total
volume of 25 μL per section) at 37°C for 20 h. Sections
were washed in the following buffers: 1 × SSC at room
temperature (RT) for 2 min and 0.5 × SSC at RT for
2 min × 2. Sections were rinsed in PBS and covered
with blocking solution (PBS, 0.1% Triton X-100, 1%
sheep serum) for 30 min. This was followed by incuba-
tion with anti-Digoxigenin-fluorescein (FITC) secondary
antibody (1:50) in blocking solution for 3 h at RT. A
final wash for 5 min in 1 × PBS and followed by mount-
ing onto glass microscope cover slides using ProLong®
Gold antifade reagent (Invitrogen). Determination of
non-specific staining was assessed by substituting 25 μL
of DIG-labeled scrambled probe in lieu of 25 μLo ft h e
DIG-labeled probe (Fig. 7).
In vitro palatal cultures
Palate cultures were set up as previously described
[4,17,18]. Briefly, timed pregnant CD-1 mice were sacri-
f i c e da tE 1 3 . 0a n dt h e i re m b r y o sr e m o v e d .T h ep a l a t e
shelves were aseptically excised from the E13.0 embryos
(staged according to [31]) in Hanks’ balanced salts solution
and placed in pairs in the proper anterior-posterior orien-
tation on Nucleopore filters (Whatman; 8.0 μm) with their
medial edges contacting and the oral side down. Shelves
were cultured in BGJb medium (Invitrogen) for 72 h at
37.0°C with 5.0% CO2. Experimental groups all had n = 5
(number of pregnant female mice from which the embryos
were extracted). From these mice, 10 embryos were ran-
domly selected, staged [31], and used for each treatment
group for a total of 30 embryos examined (10 each for
wild-type, scrambled control siRNA, and MMP-25 siRNA
groups).TGF-b3-neutralizing antibody in vitro palatal cul-
tures were incubated for 24 h.
Treatment with siRNA
The transfection of siRNA occurred as previously
described [17,18]. siRNA aliquots (500 nM) were pro-
duced by diluting a stock siRNA solution with BGJb
medium (Invitrogen) containing 0.2% TransIT-TKO®
transfection reagent (Mirus Bio, Madison, WI); the total
volume was 1.4 mL. The siRNA used was Stealth™
RNAi MMP-25 siRNA (Invitrogen) and Stealth™ RNAi
Negative Universal Control siRNA to assess for any
non-specific siRNA effects.
Scoring palate cultures
Following 72 h incubation, palate cultures were pre-
served with freshly-prepared 4.0% formaldehyde at 4.0°C
for 2 h and dehydrated with 30.0% sucrose. Frozen serial
sections (8.0 μm) were prepared and evaluated by light
microscopy to assess palatal shelf fusion [4]. Every
eighth section was examined and up to 15 sections were
examined in total. Each section was given a score based
on the completeness of fusion and quantity of remaining
epithelium, where 1 indicates no contact between the
Brown and Nazarali BMC Developmental Biology 2010, 10:93
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Page 8 of 9palate shelves and 5 indicates complete fusion as pre-
viously described [19]. A total of 10 cultures were evalu-
ated for each of the three groups: wild-type, scrambled
control siRNA, and MMP-25 siRNA.
TGF-b3-neutralizing antibody treatment
AT G F - b3-neutralizing antibody confirmed to be speci-
fic to TGF-b3 (R&D Systems, Minneapolis, MN) was
added to the BGJb culture medium (Invitrogen) to final
concentrations of 0 (wild-type control), 5, 10, and
25 μg/mL. Palatal cultures were incubated at 37°C and
5% CO2 for 24 h as previously described [32]. Following
incubation, palatal cultures (n = 10) were pooled for
RNA and protein isolation prior to quantitative real-
time PCR and western blot analysis [4].
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